Top entities: Coya Therapeutics, Wes Kaupinen, Goldman Sachs, United States — Food and Drug Administration.

What category does this event fall under?

Business — classified as conference participation.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Coya Therapeutics will present · Wes Kaupinen will participate

Is this event still developing?

This is an active story, last updated Jun 02, 2026. Coverage continues to evolve.

Business conference participation

Palvella Therapeutics to attend Goldman Sachs conference

Q: When did this event occur?

First reported Jun 02, 2026; last updated Jun 02, 2026.

Q: What is the market impact?

Direct. The announcement of Coya Therapeutics' participation in a major healthcare conference could lead to increased investor awareness and potential interest in its stock.

Analysis based on 7 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The announcement of Coya Therapeutics' participation in a major healthcare conference could lead to increased investor awareness and potential interest in its stock. This event provides a platform for Coya Therapeutics to showcase its pipeline and strategy, which could positively influence its market valuation.

Biotechnology Pharmaceuticals

Event Summary

Coya Therapeutics, a clinical-stage biopharmaceutical company, announced that its Founder and CEO, Wes Kaupinen, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 9, 2026. The company focuses on developing therapies for rare skin diseases and vascular malformations, with lead product candidates QTORIN™ rapamycin and QTORIN™ pitavastatin currently under development. A live webcast and archived replay of the fireside chat will be available on Coya Therapeutics' website.

Key Actions

100 Coya Therapeutics will present

90 Wes Kaupinen will participate

Entities Involved

stock

Coya Therapeutics

Coya Therapeutics will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, providing an opportunity to present its pipeline and strategy to investors and potentially increase its visibility and investor interest.

Importance 100 Sentiment 10

per

Wes Kaupinen

Wes Kaupinen, Founder and CEO of Coya Therapeutics, will represent the company at the conference, leading the fireside chat.

Importance 80 Sentiment 10

stock

Goldman Sachs

Goldman Sachs is hosting the 47th Annual Global Healthcare Conference 2026, providing a platform for companies like Coya Therapeutics to engage with the investment community.

Importance 40 Sentiment 0

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration is mentioned as the regulatory body whose approval is sought for Coya Therapeutics' therapies, highlighting the importance of regulatory milestones for the company's future.

Importance 20 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard